Sharescart Research Club logo

Dr. Lal Pathlabs Overview

1. Business Overview

Dr. Lal Pathlabs Ltd. is one of India's largest and most recognized diagnostic and related healthcare service providers. The company offers a comprehensive range of diagnostic tests, including routine and specialized pathology tests, molecular diagnostics, and basic radiology services. Its core business model involves collecting samples from patients (either at its collection centers, labs, or through home collection), processing these samples at its network of laboratories, and delivering accurate and timely reports. The company makes money by charging fees for these diagnostic tests and health packages. It serves individual patients, corporate clients, and refers from doctors and hospitals.

2. Key Segments / Revenue Mix

The primary revenue segment for Dr. Lal Pathlabs is pathology services, which includes a vast array of blood, urine, and other bodily fluid tests. Radiology services, while a smaller part of the business, are a growing segment. The revenue mix is diversified across walk-in patients, home collection services, doctor and hospital referrals, and corporate tie-ups. Geographically, the company has a strong presence in North and East India and is expanding its network across other regions, including West and South India. Specific percentage breakdowns for revenue segments are not publicly disclosed at a granular level.

3. Industry & Positioning

The Indian diagnostics industry is large and highly fragmented, comprising a mix of large organized players, regional chains, and numerous standalone labs. There is a discernible shift towards organized players due to their scale, advanced technology, quality accreditations, and brand trust. Dr. Lal Pathlabs is a leading organized diagnostic chain in India, holding a prominent position, especially in North India, where it has strong brand recall. It competes with other national chains like Metropolis Healthcare, SRL Diagnostics, Thyrocare Technologies, and Apollo Diagnostics, as well as hospital-attached labs and numerous unorganized players. The company is well-positioned to consolidate market share due to its established network and brand equity.

4. Competitive Advantage (Moat)

Dr. Lal Pathlabs benefits from several durable competitive advantages:

Brand & Trust: An established brand name with a long operating history (since 1949) instills high trust and perceived reliability among patients and doctors, which is crucial in healthcare.

Scale & Network: An extensive network of over 270 clinical labs and more than 5,000 patient service centers/collection centers across India provides a significant geographical reach and economies of scale in operations, procurement, and logistics.

Comprehensive Test Menu: Offers a wide array of over 4,000 routine and specialized tests, reducing the need for patients to seek multiple providers.

Quality & Accreditation: Investments in advanced technology, stringent quality controls, and national/international accreditations (NABL, CAP) ensure high accuracy and standardization, differentiating it from many smaller, unorganized labs.

5. Growth Drivers

Key factors expected to drive Dr. Lal Pathlabs' growth over the next 3-5 years include:

Increasing Healthcare Expenditure & Awareness: Rising disposable incomes, greater health consciousness, and increasing prevalence of lifestyle diseases are driving demand for diagnostic services.

Shift to Preventive Healthcare: Growing emphasis on early diagnosis, routine check-ups, and health packages.

Aging Population: An expanding elderly population leads to a higher incidence of chronic diseases requiring frequent diagnostic monitoring.

Market Consolidation: Continued shift from the unorganized to the organized sector, benefiting established players like Dr. Lal Pathlabs.

Geographic Expansion: Untapped potential in Tier 2 and Tier 3 cities, where the company is expanding its network.

Technological Advancements: Adoption of new diagnostic techniques and digital solutions (e.g., home collection apps, online reports) for enhanced convenience and efficiency.

6. Risks

Intense Competition & Price Wars: The fragmented nature of the industry and entry of new players could intensify pricing pressure, impacting margins.

Regulatory Changes: Healthcare is a highly regulated sector; changes in pricing caps, accreditation standards, data privacy laws, or other government policies could affect profitability and operations.

Reputational Risk: Any lapse in test accuracy, quality, or data security could severely damage brand trust and customer loyalty.

Technological Obsolescence: Rapid advancements in diagnostic technology necessitate continuous capital investment to remain competitive.

Talent Scarcity: Shortage of skilled pathologists and technicians could pose operational challenges and increase costs.

Economic Slowdown: A downturn in the economy could impact discretionary healthcare spending, including preventive check-ups.

7. Management & Ownership

Dr. Lal Pathlabs is a promoter-led company with a professional management team. It was founded by Dr. Maj. S.K. Lal in 1949 and is currently led by Dr. Om Prakash Lal (Chairman & Whole-time Director) and Dr. Vandana Lal (Whole-time Director), with Mr. Anjanesh Kumar Shah serving as CEO. The management team combines the vision of the founding family with professional expertise. Promoters hold a significant stake in the company, ensuring aligned long-term interests, alongside a diverse base of institutional investors (domestic and foreign) and public shareholders.

8. Outlook

Dr. Lal Pathlabs is well-positioned to capitalize on the long-term structural growth drivers of the Indian diagnostics market, including increasing healthcare awareness, rising incomes, and the shift towards organized, quality-focused diagnostic providers. Its strong brand, extensive network, and comprehensive test menu provide a significant competitive edge. However, the outlook is balanced by the inherent challenges of the highly fragmented and competitive industry, which could lead to periodic pricing pressures. The ability to sustain quality service standards across an expanding network while navigating regulatory changes and ongoing technological advancements will be crucial for maintaining its growth trajectory and profitability. Continued market share gains from the unorganized sector and successful penetration into underserved geographies are key to its future success.

Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

Dr. Lal Pathlabs Key Financials

Market Cap ₹27598 Cr.

Stock P/E 56.1

P/B 11

Current Price ₹1646.3

Book Value ₹ 149.6

Face Value 10

52W High ₹1771.3

Dividend Yield 1.25%

52W Low ₹ 1272

Dr. Lal Pathlabs Share Price

| |

Volume
Price

Dr. Lal Pathlabs Quarterly Price

Show Value Show %

Dr. Lal Pathlabs Peer Comparison

Dr. Lal Pathlabs Quarterly Results

#(Fig in Cr.) Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Net Sales 539 545 602 660 597 603 670 731 660 703
Other Income 18 18 21 22 25 26 28 25 24 24
Total Income 557 564 623 682 622 628 698 755 684 727
Total Expenditure 398 401 432 458 443 434 478 507 481 516
Operating Profit 159 163 191 224 179 195 220 249 204 211
Interest 7 7 6 6 5 5 5 5 7 6
Depreciation 36 37 35 35 36 36 35 41 42 45
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 -30 0
Profit Before Tax 116 120 150 183 138 153 181 204 124 160
Provision for Tax 34 34 42 52 40 -2 47 51 33 28
Profit After Tax 82 86 108 131 98 156 134 152 91 132
Adjustments -1 -1 -1 -2 -1 -1 -2 -2 -1 -1
Profit After Adjustments 81 85 106 129 97 155 132 151 91 131
Adjusted Earnings Per Share 4.9 5.1 6.4 7.7 5.8 9.3 7.9 9 5.4 7.8

Dr. Lal Pathlabs Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 660 791 912 1057 1203 1330 1581 2087 2017 2227 2461 2764
Other Income 13 22 28 31 46 55 51 53 42 69 93 101
Total Income 673 813 940 1088 1249 1385 1633 2140 2059 2296 2555 2864
Total Expenditure 504 584 675 793 910 987 1145 1527 1527 1617 1766 1982
Operating Profit 168 229 265 295 340 399 488 613 532 678 789 884
Interest 0 0 1 1 1 15 16 30 38 29 22 23
Depreciation 28 28 28 33 38 73 77 108 150 144 142 163
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0 -30
Profit Before Tax 140 201 237 261 301 311 394 475 344 505 625 669
Provision for Tax 43 67 81 90 100 83 98 125 103 143 133 159
Profit After Tax 96 133 156 172 200 228 296 350 241 362 492 509
Adjustments -1 -1 -1 -1 -1 -2 -5 -5 -2 -5 -5 -6
Profit After Adjustments 96 132 155 171 199 226 292 345 239 358 487 505
Adjusted Earnings Per Share 8.4 8 9.3 10.2 11.9 13.6 17.5 20.7 14.3 21.4 29.1 30.1

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 11% 6% 13% 14%
Operating Profit CAGR 16% 9% 15% 17%
PAT CAGR 36% 12% 17% 18%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 18% 19% 3% 13%
ROE Average 25% 21% 23% 26%
ROCE Average 32% 27% 30% 36%

Dr. Lal Pathlabs Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 341 507 596 788 945 1033 1245 1502 1666 1849 2173
Minority's Interest 2 3 2 4 5 21 31 35 33 36 34
Borrowings 0 0 0 0 0 0 0 167 83 0 0
Other Non-Current Liabilities -5 12 -6 -9 -20 70 83 106 93 62 21
Total Current Liabilities 112 91 85 116 138 227 274 500 470 464 402
Total Liabilities 450 613 676 899 1069 1351 1633 2310 2345 2411 2630
Fixed Assets 150 166 152 208 209 413 447 1369 1305 1194 1135
Other Non-Current Assets 18 24 57 68 47 46 41 66 67 91 132
Total Current Assets 282 424 467 623 814 893 1145 875 973 1127 1364
Total Assets 450 613 676 899 1069 1351 1633 2310 2345 2411 2630

Dr. Lal Pathlabs Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 16 23 27 29 66 129 197 244 378 264 361
Cash Flow from Operating Activities 122 159 171 197 219 284 398 447 456 535 569
Cash Flow from Investing Activities -113 -163 -137 -172 -100 -26 -212 -449 -287 -24 -303
Cash Flow from Financing Activities -1 0 -32 13 -55 -190 -139 136 -283 -414 -334
Net Cash Inflow / Outflow 8 -5 2 37 64 67 48 134 -114 97 -68
Closing Cash & Cash Equivalent 23 19 29 66 129 197 244 378 264 361 293

Dr. Lal Pathlabs Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 8.38 7.99 9.31 10.24 11.95 13.55 17.49 20.69 14.32 21.43 29.14
CEPS(Rs) 11.41 9.77 11.02 12.29 14.32 18.02 22.42 27.5 23.47 30.3 37.93
DPS(Rs) 0.77 1.23 1.5 2.25 3 6 10 6 6 12 12
Book NAV/Share(Rs) 28.78 30.64 35.33 46.19 55.04 59.99 72.31 86.59 96.44 107.7 126.57
Core EBITDA Margin(%) 23.52 26.24 26.03 24.98 24.4 25.83 27.59 26.86 24.29 27.36 28.26
EBIT Margin(%) 21.24 25.43 26.03 24.8 25.04 24.49 25.95 24.2 18.91 24.02 26.29
Pre Tax Margin(%) 21.18 25.36 25.96 24.72 24.97 23.34 24.94 22.75 17.05 22.7 25.38
PAT Margin (%) 14.62 16.84 17.05 16.25 16.66 17.11 18.75 16.78 11.95 16.27 20
Cash Profit Margin (%) 18.89 20.41 20.07 19.38 19.83 22.58 23.63 21.96 19.4 22.72 25.76
ROA(%) 24.67 25.06 24.13 21.81 20.38 18.81 19.87 17.77 10.36 15.23 19.53
ROE(%) 37.14 32.45 28.45 25.32 23.76 23.74 26.89 26.45 15.8 21.27 25.15
ROCE(%) 48.87 47.43 43.07 37.9 34.78 32.94 36.03 32.67 20.34 27.89 31.53
Receivable days 15.53 15.51 15.62 14.32 14.31 14.35 13.63 13.3 14.14 12.15 12.27
Inventory Days 7.18 6.64 6.49 7.81 8.47 11.73 11.49 8.31 7.81 5.83 5.45
Payable days 87.86 80.66 87.64 95.14 101.04 120.69 120.3 105.92 123.86 138.53 146.09
PER(x) 0 57.63 51.99 42.7 44.12 51.69 77.38 63.02 63.8 52.8 42.52
Price/Book(x) 0 15.04 13.69 9.47 9.58 11.68 18.72 15.06 9.48 10.5 9.79
Dividend Yield(%) 0 0.27 0.31 0.51 0.57 0.86 0.74 0.46 0.66 1.06 0.97
EV/Net Sales(x) -0.1 9.36 8.55 6.6 6.9 8.35 13.68 10.28 7.34 8.15 8.08
EV/Core EBITDA(x) -0.4 32.28 29.42 23.63 24.43 27.87 44.38 34.99 27.86 26.74 25.19
Net Sales Growth(%) 18.22 19.97 15.3 15.84 13.86 10.55 18.86 32.01 -3.38 10.4 10.54
EBIT Growth(%) 17.35 43.6 18.04 10.37 14.96 8.11 25.96 23.09 -24.51 40.24 21
PAT Growth(%) 20.15 38.15 16.78 10.39 16.72 13.53 30.27 18.15 -31.18 50.28 35.87
EPS Growth(%) 17.26 -4.64 16.4 10.09 16.65 13.43 29.07 18.25 -30.75 49.58 35.99
Debt/Equity(x) 0 0 0 0 0 0 0 0.24 0.15 0.05 0
Current Ratio(x) 2.52 4.67 5.5 5.37 5.88 3.93 4.18 1.75 2.07 2.43 3.39
Quick Ratio(x) 2.39 4.51 5.29 5.14 5.68 3.68 4.02 1.65 2 2.35 3.3
Interest Cover(x) 346.2 404.57 340.29 311.72 359.22 21.28 25.65 16.74 10.16 18.22 29.01
Total Debt/Mcap(x) 0 0 0 0 0 0 0 0.02 0.02 0 0

Dr. Lal Pathlabs Shareholding Pattern

# Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Promoter 54.6 54.6 54.6 53.92 53.91 53.91 53.79 53.21 53.21 53.21
FII 25.35 26.15 25.42 26.82 26.82 23.91 21.68 21.86 20.29 17.18
DII 9.56 9.69 12.71 12.89 13.17 16.08 17.79 18.34 19.07 21.25
Public 10.49 9.56 7.26 6.37 6.11 6.1 6.74 6.58 7.43 8.36
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Dr. Lal Pathlabs News

Dr. Lal Pathlabs Pros & Cons

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 21%
  • Company is almost debt free.

Cons

  • Debtor days have increased from 138.53 to 146.09days.
  • Stock is trading at 11 times its book value.
whatsapp